Last reviewed · How we verify
Cincain (CINCHOPHEN)
Cinchophen (Cincain) is a marketed drug primarily indicated for gout, positioned in a competitive landscape alongside colchicine, which has been FDA-approved since 1961 and is patent-protected until October 6, 2028. Its key strength lies in its unique mechanism of action, blocking the enzyme that degrades cAMP and cGMP, potentially offering a distinct therapeutic benefit. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | CINCHOPHEN |
|---|---|
| Drug class | cinchophen |
| Target | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Gout